Cited by 120Metabolism, Diabetes, and CancerProtease and Inhibitor MechanismsMechanisms of cancer metastasis

Effect of metformin on the proliferation, migration, and MMP-2 and-9 expression of human umbilical vein endothelial cells

Open access
ESFAHANIAN, NILUFAR, SHAKIBA, YADOLLAH, NIKBIN, BEHROZ, SORAYA, HAMID, MALEKI-DIZAJI, NASRIN, GHAZI-KHANSARI, MAHMOOD, GARJANI, ALIREZA·2012·Molecular Medicine Reports

Abstract

Recent epidemiological studies have demonstrated that metformin lowers the risk of several types of cancer in diabetic patients. Matrix metalloproteinases (MMPs) play a crucial role in the degradation of the vascular basement membrane extracellular matrix proteins, thereby promoting endothelial cell invasion, migration and angiogenesis in the incidence and progression of tumors. The aim of this study was to investigate the effects of metformin on human umbilical vein endothelial cell (HUVEC) proliferation and migration, as well as on MMP-2 and MMP-9 expression. Cell proliferation was determined by cell counting and MTT colorimetric assays. Cell migration was assessed by the wound repair method. Quantitative real-time reverse transcription PCR was performed to quantify the mRNA expression of MMPs. Metformin at concentrations of 0.5-3.0 mM effectively reduced the number of endothelial cells by 5.5-55%, without being cytotoxic to the cells. Similarly, cell proliferation and migration were markedly inhibited by metformin. In addition, treatment with metformin demonstrated a strong (P<0.001) suppressive effect on the mRNA levels of MMP-2 and -9 in the endothelial cells. The inhibitory effects of metformin on endothelial cell number, migration, and MMP expression were reversed partially by compound C, which is an inhibitor of AMP-activated protein kinase (AMPK). The present study reports that metformin considerably inhibited the proliferation, migration, and MMP-2 and -9 expression of HUVECs, and the effect was partially AMPK-dependent. The obtained findings provide a molecular rationale, whereby metformin can exert anticancer effects.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/mmr.2012.753

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Animal studies in FXS have demonstrated a hyperactive insulin receptor and up-regulation of mTORC1 and MAPK/ERK signaling pathways, as well as elevation of MMP-9 levels in the absence of FMRP.

    “Animal studies in FXS have demonstrated a hyperactive insulin receptor and up-regulation of the mammalian target of rapamycin complex 1 (mTORC1) and mitogen-activated protein kinase/extracellular signal-related kinases (MAPK/ERK) signaling pathways, as well as elevation of MMP-9 levels in the absence of FMRP, the protein produced by the FMR1 gene [106–108].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 46 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
ESFAHANIAN, N., SHAKIBA, Y., NIKBIN, B., SORAYA, H., MALEKI-DIZAJI, N., GHAZI-KHANSARI, M., & GARJANI, A.
Affiliations
  • Tabriz University of Medical Sciences (IR)
  • Tehran University of Medical Sciences (IR)
Corresponding author
GARJANI, ALIREZA
Venue
Molecular Medicine Reports
Published
2012-01-12
Volume
5
Issue
4
Pages
1068-1074
ISSN
  • 1791-2997 (ISSN-L)
  • 1791-3004
OpenAlex
W2037187996
Cited by
120
References
46
Citations by year
2026: 1 · 2025: 1 · 2024: 4 · 2023: 15 · 2022: 4 · 2021: 15 · 2020: 11 · 2019: 16 · 2018: 9 · 2017: 17 · 2016: 5 · 2015: 11 · 2014: 4 · 2013: 4 · 2012: 3
FWCI
2.83
Type
journal article
Language
en
Open access
Locations
  • Molecular Medicine Reports (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Tabriz University of Medical Sciences
  • Tehran University of Medical Sciences and Health Services
  • University of Tabriz
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Keywords
metformin, human umbilical vein endothelial cells, endothelial cell proliferation, endothelial cell migration, MMP-2, MMP-9, matrix metalloproteinases, AMPK, compound C, angiogenesis, anticancer effects, diabetes mellitus
MeSH terms
Cell Movement, Humans, Hypoglycemic Agents, Metformin, Pyrazoles, Pyrimidines, Gene Expression Regulation, Enzymologic, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, Cell Proliferation, AMP-Activated Protein Kinases, Human Umbilical Vein Endothelial Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review